The Novel, Orally Active, Delta Opioid Rwj-394674 is Biotransformed to the Potent Mu Opioid Rwj-413216.
From: Johnson & Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA. ecodd@prdus.jnj.com
The Journal of pharmacology and experimental therapeutics
- Publish Date: Sep 2006
- ISSN: 0022-3565
- Volume: 318
- Issue: 3
- Pages: 1273-9
- Medium: Print
- Language: English
- Citation (JAMA): Codd E E, Carson J R, Colburn R W, et al. The Novel, Orally Active, Delta Opioid Rwj-394674 is Biotransformed to the Potent Mu Opioid Rwj-413216.. J. Pharmacol. Exp. Ther. Sep 2006;318:1273-9
Abstract
Although the mu opioid receptor is the primary target of marketed opioid analgesics, several studies suggest the advantageous effect of combinations of mu and delta opioids. The novel compound RWJ-394674 [N,N-diethyl-4-[(8-phenethyl-8-azabicyclo]3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide]; bound with high affinity to the delta opioid receptor (0.2 nM) and with weaker affinity to the mu opioid receptor (72 nM). 5’-O-(3-[(35)S]-thio)triphosphate binding assay demonstrated its delta agonist function. Surprisingly given this pharmacologic profile, RWJ-394674 exhibited potent oral antinociception (ED(50) = 10.5 micromol/kg or 5 mg/kg) in the mouse hot-plate (48 degrees C) test and produced a moderate Straub tail. Antagonist studies in the more stringent 55 degrees C hot-plate test demonstrated the antinociception produced by RWJ-394674 to be sensitive to the nonselective opioid antagonist naloxone as well as to the delta- and mu-selective antagonists, naltrindole and beta-funaltrexamine, respectively. In vitro studies demonstrated that RWJ-394674 was metabolized by hepatic microsomes to its N-desethyl analog, RWJ-413216 [N-ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide], which, in contrast to RWJ-394674, had a high affinity for the mu rather than the delta opioid receptor and was an agonist at both. Pharmacokinetic studies in the rat revealed that oral administration of RWJ-394674 rapidly gave rise to detectable plasma levels of RWJ-413216, which reached levels equivalent to those of RWJ-394674 by 1 h. RWJ-413216 itself demonstrated a potent oral antinociceptive effect. Thus, RWJ-394674 is a delta opioid receptor agonist that appears to augment its antinociceptive effect through biotransformation to a novel mu opioid receptor-selective agonist.
Mesh Headings (Keywords): Administration, Oral, Analgesics, Opioid, Animals, Bicyclo Compounds, Heterocyclic, Female, Male, Mice, Microsomes, Liver, Rats, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Opioid, delta, Receptors, Opioid, mu
Check for Full Text / PubMed Unique Identifier (PMID): 16766719
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.